title: Hepatitis in an infant treated with octreotide for congenital hyperinsulinism.
abstract: Congenital hyperinsulinism is characterized by hypoglycemia caused by several genetic disorders of inappropriate insulin secretion. Octreotide, an analogue of somatostatin, plays a major role in the pharmaceutical treatment of this condition. A 9-month-old infant treated with octreotide developed anicteric hepatitis with no other proven cause. After the discontinuation of this drug, the liver enzymes declined rapidly. Liver function tests should be followed in patients receiving octreotide.
authors: Armon Child Center, Haifa, Israel. ilanaza2@clalit.org.il
authors: Ilana
authors: I
authors: Koren
authors: Arieh
authors: A
authors: Riskin
authors: Winfried
authors: W
authors: Barthlen
authors: David
authors: D
authors: Gillis
mesh_terms: D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis*; D044903:Congenital Hyperinsulinism / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008111:Liver Function Tests; D015282:Octreotide / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide